Published in Blood Weekly, February 13th, 2003
"Thus, although conventional chemotherapy regimens often ablate actively cycling leukemic blast cells, the primitive LSC population is likely to be drug-resistant," explained M. L. Guzman and coworkers. "Moreover, given the quiescent nature of LSCs, current drugs may not effectively distinguish between malignant stem cells...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.